CA2242590A1 - T cells mediating an immune response and methods of use - Google Patents

T cells mediating an immune response and methods of use Download PDF

Info

Publication number
CA2242590A1
CA2242590A1 CA002242590A CA2242590A CA2242590A1 CA 2242590 A1 CA2242590 A1 CA 2242590A1 CA 002242590 A CA002242590 A CA 002242590A CA 2242590 A CA2242590 A CA 2242590A CA 2242590 A1 CA2242590 A1 CA 2242590A1
Authority
CA
Canada
Prior art keywords
tumor
cell
cells
human
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002242590A
Other languages
English (en)
French (fr)
Inventor
David Berd
Giorgio Parmiani
Andrea Anichini
Marialuisa Sensi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2242590A1 publication Critical patent/CA2242590A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002242590A 1996-10-04 1997-10-02 T cells mediating an immune response and methods of use Abandoned CA2242590A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2700296P 1996-10-04 1996-10-04
US60/027,002 1996-10-04

Publications (1)

Publication Number Publication Date
CA2242590A1 true CA2242590A1 (en) 1998-04-09

Family

ID=21835095

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002242590A Abandoned CA2242590A1 (en) 1996-10-04 1997-10-02 T cells mediating an immune response and methods of use

Country Status (7)

Country Link
EP (1) EP0871480A4 (de)
AU (1) AU4976697A (de)
CA (1) CA2242590A1 (de)
IL (1) IL125747A0 (de)
NZ (1) NZ330995A (de)
PL (1) PL328790A1 (de)
WO (1) WO1998014206A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301174A (zh) * 1998-04-09 2001-06-27 托马斯杰斐逊大学 诱导抗黑素瘤患者肺转移的抗－肿瘤应答的方法
AU3786999A (en) * 1998-05-04 1999-11-23 Thomas Jefferson University Composition comprising tumor cells and extracts and method of using thereof
DE60031100T2 (de) 1999-03-16 2007-03-08 Thomas Jefferson University Hapten modifizierte tumorzellen und verfahren zur herstellung und deren verwendung
US7297330B2 (en) * 2000-02-04 2007-11-20 Thomas Jefferson University Low dose haptenized tumor cell and tumor cell extract immunotherapy
EP1551225A4 (de) 2002-06-10 2011-05-25 Avax Technologies Inc Kryokonservierung von haptenmodifizierten tumorzellen
US20070134670A1 (en) * 2003-12-12 2007-06-14 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
EP3737692A4 (de) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. Calreticulin-bindende konstrukte und gentechnisch veränderte t-zellen zur behandlung von krankheiten
EP3818083A2 (de) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr-antikörpermoleküle und ihre verwendungen
GB2595980B (en) * 2019-01-04 2023-06-14 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3806565A1 (de) * 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
ATE272113T1 (de) * 1994-02-16 2004-08-15 Crucell Holland Bv Melanoma-assoziierte antigene, epitope davon und impstoffe gegen melanoma
KR19990022592A (ko) * 1995-06-07 1999-03-25 아브람 엠. 골드핑거 합텐으로 변형된 종양 세포 추출물과 암 치료 또는 스크리닝 방법

Also Published As

Publication number Publication date
EP0871480A1 (de) 1998-10-21
EP0871480A4 (de) 2001-04-04
AU4976697A (en) 1998-04-24
IL125747A0 (en) 1999-04-11
NZ330995A (en) 2000-12-22
PL328790A1 (en) 1999-02-15
WO1998014206A1 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
Barber et al. Chimeric NKG2D receptor–bearing T cells as immunotherapy for ovarian cancer
EP2427485B1 (de) Cd133-epitope
KR101610353B1 (ko) Ｃｄｃａ１ 펩티드 및 이를 포함하는 약학적 조성물
Sensi et al. Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.
EP2465520A2 (de) Epitop-Sequenzen
Romero et al. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination
Machlenkin et al. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy
US20090074800A1 (en) Cancer antigen and use thereof
KR20100090710A (ko) 암 백신 조성물
KR20230107206A (ko) Ras 신생항원 및 이의 용도
CA2242590A1 (en) T cells mediating an immune response and methods of use
KR101757798B1 (ko) 면역 유도제
KR100900742B1 (ko) 인간 간암 동물모델 및 이를 이용한 수지상세포-유래 간암면역치료제의 예방 및 치료 효능을 분석하는 방법
Kirkin et al. Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines
EP2216041A1 (de) Verfahren zur induktion einer zytotoxischen t-zelle, zytotoxischer t-zell-induktor und pharmazeutische zusammensetzung sowie impfstoff mit dem induktor
KR19990022592A (ko) 합텐으로 변형된 종양 세포 추출물과 암 치료 또는 스크리닝 방법
EP1131426B1 (de) Von mage-10 oder mage-8 abgeleitete hla-a2.1-bindende oligopeptide
CA3080835A1 (en) Immunotherapeutic methods for treating and/or preventing lung cancer
Adair et al. The TAG Family of Cancer/Testis Antigens is Widely Expressed in a Variety of Malignancies and Gives Rise to HLA-A2–Restricted Epitopes
JP4943348B2 (ja) 免疫学的及び抗腫瘍活性を有するチミジル酸シンターゼ由来のポリエピトープペプチド
CA3253072A1 (en) Method of preparing and expanding a population of immune cells for cancer therapy, potency assay for tumor recognition, biological vaccine preparation and epitope target for antibodies
WO2000020564A1 (en) T cells mediating an immune response and methods of use
JP2010530748A (ja) プレプロカルシトニン抗原ｔエピトープ
EP1403283A1 (de) Tumorantigen
JP2005504038A (ja) ヘパリン結合性上皮増殖因子阻害剤又はその受容体の阻害剤の、骨髄腫の治療に有用な薬剤の調製のための使用

Legal Events

Date Code Title Description
FZDE Discontinued